Indian pharmaceutical industry to sustain at 8-10 per cent in FY2024: ICRA insights https://ift.tt/bp4iHkh

Growth in recent years has largely been supported by price increases and new product introductions even as volume growth has been negative or 2-3 per cent at best. Acute therapies, accounting for 62-65 per cent of the IPM, have continued to outpace growth in chronic therapies since FY2022. However, the trend is expected to reverse going forward.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/U2IhkHz